JANX
Janux Therapeutics Inc

1,657
Mkt Cap
$832.06M
Volume
1.08M
52W High
$35.34
52W Low
$12.12
PE Ratio
-7.41
JANX Fundamentals
Price
$13.58
Prev Close
$13.95
Open
$14.06
50D MA
$13.70
Beta
1.47
Avg. Volume
1.14M
EPS (Annual)
-$1.83
P/B
0.86
Rev/Employee
$91,743.12
$89.28
Loading...
Loading...
News
all
press releases
Cantor Fitzgerald Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price
Cantor Fitzgerald reduced their price target on shares of Janux Therapeutics from $150.00 to $100.00 and set an "overweight" rating on the stock in a research report on Friday...
MarketBeat·15d ago
News Placeholder
More News
News Placeholder
Janux Therapeutics, Inc. Q4 Loss Rises
(RTTNews) - Janux Therapeutics, Inc. (JANX) released Loss for its fourth quarter of -$42.40 million...
Nasdaq News: Markets·15d ago
News Placeholder
Janux Therapeutics (NASDAQ:JANX) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS
Janux Therapeutics (NASDAQ:JANX - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of...
MarketBeat·15d ago
News Placeholder
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth...
Business Wire·16d ago
News Placeholder
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of "Moderate Buy" from Analysts
Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fifteen research firms that are presently covering the stock, Marketbeat.com...
MarketBeat·16d ago
News Placeholder
Readystate Asset Management LP Boosts Stock Holdings in Janux Therapeutics, Inc. $JANX
Readystate Asset Management LP lifted its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 38.0% in the 3rd quarter, according to the company in its most recent 13F filing with the...
MarketBeat·24d ago
News Placeholder
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been...
Business Wire·25d ago
News Placeholder
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week Low - Should You Sell?
Janux Therapeutics (NASDAQ:JANX) Hits New 52-Week Low - Time to Sell...
MarketBeat·1mo ago
News Placeholder
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 319.2% in Janux Therapeutics (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·1mo ago
News Placeholder
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fifteen research firms that are currently covering the stock...
MarketBeat·1mo ago
<
1
2
...
>

Latest JANX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.